Top

Published in:

01-06-2016 | CONTRAST MEDIA

Gadolinium-based contrast agents: did we miss something in the last 25 years?

Authors: Bruno Beomonte Zobel, Carlo Cosimo Quattrocchi, Yuri Errante, Rosario Francesco Grasso

Published in: La radiologia medica | Issue 6/2016

Abstract

In the last 24 months, several clinical and experimental studies, suggested first and demonstrated later, a progressive concentration of Gadolinium in the brain of normal renal function patients, following repeated injections of some of the commercially approved Gadolinium-Based Contrast Agents. Although, till now, Gadolinium brain deposits have not been associated to any kind of neurological signs or symptoms, they oblige the radiology community to modify the actual approach in using Gadolinium contrast media in daily practice, to reduce unknown possible risks for patients.

Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium (III) chelates as MRI contrast agents: structure, dynamics and applications. Chem Rev 99:2293–2352CrossRefPubMed

Palasz A, Czekaj P (2000) Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 47:1107–1114PubMed

Lowe A, Balzer T, Hirt U (2005) Interference of Gadolinium containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol 40:521–525CrossRefPubMed

Swaminathan S, Horn TD, Pellowski D et al (2007) Nephrogenic systemic fibrosis, Gadolinium and iron mobilization. New Engl J Med 357:720–722CrossRefPubMed

Ersoy H, Rybicki FJ (2007) Biochemical safety profiles of Gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 25:1190–1197CrossRef

Yang L, Krefting I, Gorovets A et al (2012) Nephrogenic systemic fibrosis and class labeling of Gadolinium-based contrast agents by the food and drug administration. Radiology 265:248–253CrossRefPubMed

Idee JM, Port M, Raynal I et al (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576CrossRefPubMed

Runge VM (2015) Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of Gadolinium-based contrast agents in healthy rats. Invest Radiol 50:481–482CrossRefPubMed

Prince MR, Zhang H, Zou Z, Staron RB, Brill PW (2011) Incidence of immediate Gadolinium contrast media reactions. AJR 196:W138–W143CrossRefPubMed

10.

Bruder O, Schneider S, Pilz G et al (2015) Update on acute adverse reaction to Gadolinium based contrast agents in cardiovascular MR. Large multi-national and multi-ethnical population experience with 37.788 patients from the EuroCMR registry. J Cardiovasc Magn Reson 17:14 (Epub ahead of print) CrossRef

11.

Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis ? Nephrol Dial Transpl 21:1104–1108CrossRef

12.

Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362CrossRefPubMed

13.

Idee JM, Port M, Dencausse A, Lancelot E, Corot C (2009) Involvement of Gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47:855–869CrossRefPubMed

14.

Idee JM, Fretellier N, Robic C, Corot C (2014) The role of Gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update. Crit Rev Toxicol 44:895–913CrossRefPubMed

15.

Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ (2008) Stability of Gadolinium-based contrast agents in human serum at 37 °C. Invest Radiol 43:817–828CrossRefPubMed

16.

European Society of Urogenital Radiology, Contrast Medium Safety Committee Guidelines (2008). http://www.esur.org/esur-guidelines/

17.

Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to Gadolinium. JAMA Dermatol 151:1117–1120CrossRefPubMed

18.

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a Gadolinium-based contrast material. Radiology 270:834–841CrossRefPubMed

19.

Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Beomonte Zobel B, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus, on unenhanced Magnetic Resonance images, is associated with cumulative doses of intravenously administered Gadodiamide, in patients with normal renal function, suggesting dechelation. Invest Radiol 49:685–690CrossRefPubMed

20.

Kanda T, Osawa M, Oba H et al (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic Gadolinium chelate administration. Radiology 275:803–809CrossRefPubMed

21.

Quattrocchi CC, Mallio CA, Errante Y et al (2015) Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50:470–472CrossRefPubMed

22.

Radbruch A, Weberling LD, Pascal J et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791CrossRefPubMed

23.

Ramalho J, Castillo M, AlObaidy M et al. (2015) High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear Gadolinium-based contrast agents. Radiology 276:836–844CrossRef

24.

Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus GdHP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39:138–142CrossRefPubMed

25.

White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to Gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest Radiol 41:272–278CrossRefPubMed

26.

Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE (2009) Incorporation of excess Gadolinium into human bone from medical contrast agents. Metallomics 1:479–488CrossRefPubMed

27.

McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial Gadolinium deposition after contrast-enhanced MR Imaging. Radiology 275:772–782CrossRefPubMed

28.

Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based contrast agents accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232CrossRefPubMed

29.

Robert P, Lehericy S, Grand S et al (2015) T1-weighted hypersignal in the deep cerebellar nuclei following repeated administration of Gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 50:473–480CrossRefPubMedPubMedCentral

30.

Kimura J, Ishiguchi T, Matsuda J et al (2005) Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 23:322–326PubMed

31.

Vorobiov M, Basok A, Tovbin D et al (2003) Iron-mobilizing properties of the Gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transpl 18:884–887CrossRef

32.

Idee JM, Berthommier C, Goulas V et al (1998) Haemodynamic effects of macrocyclic and linear Gadolinium chelates in rats: role of calcium and transmetallation. Biometals 11:113–123CrossRefPubMed

33.

Birka M, Wentker KS, Lusmoller E et al (2015) Diagnosis of Nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 87:3321–3328CrossRefPubMed

34.

Fretellier N, Idee JM, Dencausse A et al (2011) Comparative in vivo dissociation of Gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 46:292–300CrossRefPubMed

35.

Roberts DR, Holden K R (2015) Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of Gadolinium contrast. Brain Dev. doi:10.1016/j.braindev.2015.08.009

36.

Kanal E, Tweedle MF (2015) Residual or retained Gadolinium: practical implications for radiologists and our patients. Radiology 275:630–634CrossRefPubMed

37.

European Medicines Agency (EMA) Doc. Ref. EMEA/727399/2009 rev. EMEA/H/A-31/1097 London, 1 July 2010

Title: Gadolinium-based contrast agents: did we miss something in the last 25 years?
Authors: Bruno Beomonte Zobel
Carlo Cosimo Quattrocchi
Yuri Errante
Rosario Francesco Grasso
Publication date: 01-06-2016
Publisher: Springer Milan
Published in: La radiologia medica / Issue 6/2016
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-015-0614-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gadolinium-based contrast agents: did we miss something in the last 25 years?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Potential causes for obtaining non-diagnostic results from fine needle aspiration biopsy of thyroid nodules

The utility of the high-resolution ultrasound technique in the evaluation of autologous adipose tissue lipofilling, used for the correction of post-surgical, post-traumatic and post-burn scars

ePTFE stent graft in non-steno-occlusive arterial disease: 2 centers retrospective study

Added value of lung window in detecting drug mules on non-contrast abdominal computed tomography

Indications and efficacy of O2–O3 intradiscal versus steroid intraforaminal injection in different types of disco vertebral pathologies: a prospective randomized double-blind trial with 517 patients

Combined multimodal co-registration of PET/CT and MRI images increases diagnostic accuracy in squamous cell carcinoma staging